Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZMPB-NK006
- Development stage
- Unknown
- Lead developer
- Hebei Meiosai Biotechnology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ZMPB-NK006 is an allogeneic, "off-the-shelf" cell therapy consisting of natural killer (NK) cells derived from umbilical cord blood. Developed by Hebei Meiosai Biotechnology, this product is designed to treat advanced solid tumors by leveraging the innate anti-tumor activity of NK cells. These cells are capable of recognizing and lysing malignant cells through a balance of activating and inhibitory receptors, independent of major histocompatibility complex (MHC) restriction. Upon activation, ZMPB-NK006 cells release cytotoxic granules containing perforin and granzymes to induce apoptosis in target tumor cells and secrete pro-inflammatory cytokines to modulate the tumor microenvironment. The use of umbilical cord blood as a source provides a high yield of potent, proliferative NK cells with a lower risk of graft-versus-host disease (GvHD) compared to adult peripheral blood sources.
- Other names
- Umbilical cord blood-derived natural killer cell injection脐带血来源自然杀伤细胞注射液
02
Targets
NKG2DL (NKG2D ligand family)NKG2D (Natural killer group 2 member D receptor)
Beyond the preview
Go deeper on ZMPB-NK006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZMPB-NK006.